<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 18: Drug Interactions: Pharmacokinetic Parameters for Coadministered Drugs in the Presence of REYATAZ<sup>a</sup>
</caption>
<col width="20%"></col>
<col width="22%"></col>
<col width="21%"></col>
<col width="18%"></col>
<col width="18%"></col>
<col width="18%"></col>
<thead>
<tr>
<th rowspan="2" stylecode="Botrule Toprule " valign="top">
<content stylecode="bold">Coadministered Drug</content>
</th>
<th rowspan="2" stylecode="Botrule Toprule " valign="top">
<content stylecode="bold">Coadministered Drug</content>
<br/>
<content stylecode="bold">Dose/Schedule</content>
</th>
<th rowspan="2" stylecode="Botrule Toprule " valign="top">
<content stylecode="bold">REYATAZ</content>
<br/>
<content stylecode="bold">Dose/Schedule</content>
</th>
<th colspan="3" stylecode="Toprule " valign="top">
<content stylecode="bold">Ratio (90% Confidence Interval) of Coadministered Drug Pharmacokinetic Parameters with/without REYATAZ;</content>
<br/>
<content stylecode="bold">No Effect = 1.00</content>
</th>
</tr>
<tr>
<th stylecode="Botrule " valign="top">
<content stylecode="bold">C<sub>max</sub>
</content>
</th>
<th stylecode="Botrule " valign="top">
<content stylecode="bold">AUC</content>
</th>
<th stylecode="Botrule " valign="top">
<content stylecode="bold">C<sub>min</sub>
</content>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="12" stylecode="Botrule" valign="top">
<sup>a</sup> Data provided are under fed conditions unless otherwise noted.<br/>
<sup>b</sup> All drugs were given under fasted conditions.<br/>
<sup>c</sup> 400 mg ddI EC and REYATAZ were administered together with food on Days 8 and 19.<br/>
<sup>d</sup> Upon further dose normalization of ethinyl estradiol 25 mcg with atazanavir relative to ethinyl estradiol 35 mcg without atazanavir, the ratio of geometric means (90% confidence intervals) for C<sub>max</sub>, AUC, and C<sub>min</sub> were 0.82 (0.73, 0.92), 1.06 (0.95, 1.17), and 1.35 (1.11, 1.63), respectively.<br/>
<sup>e</sup> Upon further dose normalization of ethinyl estradiol 35 mcg with atazanavir/ritonavir relative to ethinyl estradiol 25 mcg without atazanavir/ritonavir, the ratio of geometric means (90% confidence intervals) for C<sub>max</sub>, AUC, and C<sub>min</sub> were 1.17 (1.03, 1.34), 1.13 (1.05, 1.22), and 0.88 (0.77, 1.00), respectively.<br/>
<sup>f</sup> All subjects were on a 28 day lead-in period; one full cycle of Ortho Tri-Cyclen<sup>®</sup>. Ortho Tri-Cyclen<sup>®</sup> contains 35 mcg of  ethinyl estradiol. Ortho Tri-Cyclen<sup>®</sup> LO contains 25 mcg of ethinyl estradiol. Results were dose normalized to an ethinyl  estradiol dose of 35 mcg.<br/>
<sup>g</sup> 17-deacetyl norgestimate is the active component of norgestimate.<br/>
<sup>h</sup> (R)-methadone is the active isomer of methadone.<br/>
<sup>i</sup> Study was conducted in HIV-infected individuals.<br/>
<sup>j</sup> Subjects were treated with nevirapine prior to study entry.<br/>
<sup>k</sup> Omeprazole was used as a metabolic probe for CYP2C19. Omeprazole was given 2 hours after REYATAZ on Day 7; and was given alone 2 hours after a light meal on Day 20.<br/>
<sup>l</sup> Not the recommended therapeutic dose of atazanavir.<br/>
<sup>m</sup> When compared to rifabutin 150 mg QD alone d1−10 (n=14). Total of rifabutin + 25-O-desacetyl-rifabutin: AUC 2.19 (1.78, 2.69).<br/>
<sup>n</sup> Rosiglitazone used as a probe substrate for CYP2C8.<br/>
<sup>o</sup> Mean ratio (with/without coadministered drug). ↑ indicates an increase in rosuvastatin exposure.<br/>
<sup>p</sup> The combination of atazanavir and saquinavir 1200 mg QD produced daily saquinavir exposures similar to the values produced by the standard therapeutic dosing of saquinavir at 1200 mg TID. However, the C<sub>max</sub> is about 79% higher than that for the standard dosing of saquinavir (soft gelatin capsules) alone at 1200 mg TID.<br/>
<sup>q</sup> Note that similar results were observed in a study where administration of tenofovir and REYATAZ was separated by 12 hours.<br/>
<sup>r</sup> Administration of tenofovir and REYATAZ was temporally separated by 12 hours.<br/>NA = not available.<br/>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Toprule ">
<paragraph>acetaminophen</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>1 gm BID, d 1−20 (n=10)</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 11−20 (n=10)</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>0.87<br/>(0.77, 0.99)</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>0.97<br/>(0.91, 1.03)</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>1.26<br/>(1.08, 1.46)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>atenolol</paragraph>
</td>
<td align="center">
<paragraph>50 mg QD, d 7−11 (n=19) and d 19−23</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−11 (n=19)</paragraph>
</td>
<td align="center">
<paragraph>1.34<br/>(1.26, 1.42)</paragraph>
</td>
<td align="center">
<paragraph>1.25<br/>(1.16, 1.34)</paragraph>
</td>
<td align="center">
<paragraph>1.02<br/>(0.88, 1.19)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>boceprevir</paragraph>
</td>
<td align="center">
<paragraph>800 mg TID, d 1−6, 25−31</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 10−31</paragraph>
</td>
<td align="center">
<paragraph>0.93<br/>(0.80, 1.08)</paragraph>
</td>
<td align="center">
<paragraph>0.95<br/>(0.87, 1.05)</paragraph>
</td>
<td align="center">
<paragraph>0.82<br/>(0.68, 0.98)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>clarithromycin</paragraph>
</td>
<td align="center">
<paragraph>500 mg BID, d 7−10 (n=21) and d 18−21</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−10 (n=21)</paragraph>
</td>
<td align="center">
<paragraph>1.50<br/>(1.32, 1.71)<br/>OH-<br/>clarithromycin:<br/>0.28<br/>(0.24, 0.33)</paragraph>
</td>
<td align="center">
<paragraph>1.94<br/>(1.75, 2.16)<br/>OH-<br/>clarithromycin:<br/>0.30<br/>(0.26, 0.34)</paragraph>
</td>
<td align="center">
<paragraph>2.60<br/>(2.35, 2.88)<br/>OH-<br/>clarithromycin:<br/>0.38<br/>(0.34, 0.42)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>didanosine (ddI) (buffered tablets) plus stavudine<br/>(d4T)<sup>b</sup>
</paragraph>
</td>
<td align="center">
<paragraph>ddI: 200 mg × 1 dose,<br/>d4T: 40 mg × 1 dose (n=31)</paragraph>
</td>
<td align="center">
<paragraph>400 mg × 1 dose simultaneous with ddI and d4T (n=31)</paragraph>
</td>
<td align="center">
<paragraph>ddI: 0.92<br/>(0.84, 1.02)<br/>d4T: 1.08<br/>(0.96, 1.22)</paragraph>
</td>
<td align="center">
<paragraph>ddI: 0.98<br/>(0.92, 1.05)<br/>d4T: 1.00<br/>(0.97, 1.03)</paragraph>
</td>
<td align="center">
<paragraph>NA<br/>
<br/>d4T: 1.04<br/>(0.94, 1.16)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>ddI (enteric-coated [EC] capsules)<sup>c</sup>
</paragraph>
</td>
<td align="center">
<paragraph>400 mg d 1 (fasted), d 8 (fed) (n=34)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 2−8 (n=34)</paragraph>
</td>
<td align="center">
<paragraph>0.64<br/>(0.55, 0.74)</paragraph>
</td>
<td align="center">
<paragraph>0.66<br/>(0.60, 0.74)</paragraph>
</td>
<td align="center">
<paragraph>1.13<br/>(0.91, 1.41)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph> </paragraph>
</td>
<td align="center">
<paragraph>400 mg d 1 (fasted), d 19 (fed) (n=31)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 9−19 (n=31)</paragraph>
</td>
<td align="center">
<paragraph>0.62<br/>(0.52, 0.74)</paragraph>
</td>
<td align="center">
<paragraph>0.66<br/>(0.59, 0.73)</paragraph>
</td>
<td align="center">
<paragraph>1.25<br/>(0.92, 1.69)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>diltiazem</paragraph>
</td>
<td align="center">
<paragraph>180 mg QD, d 7−11 (n=28) and d 19−23</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−11 (n=28)</paragraph>
</td>
<td align="center">
<paragraph>1.98<br/>(1.78, 2.19)<br/>desacetyl-<br/>diltiazem:<br/>2.72<br/>(2.44, 3.03)</paragraph>
</td>
<td align="center">
<paragraph>2.25<br/>(2.09, 2.16)<br/>desacetyl-<br/>diltiazem:<br/>2.65<br/>(2.45, 2.87)</paragraph>
</td>
<td align="center">
<paragraph>2.42<br/>(2.14, 2.73)<br/>desacetyl-<br/>diltiazem:<br/>2.21<br/>(2.02, 2.42)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>ethinyl estradiol &amp; norethindrone<sup>d</sup>
</paragraph>
</td>
<td align="center">
<paragraph>Ortho-Novum<sup>®</sup> 7/7/7 QD, d 1−29 (n=19)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 16−29 (n=19)</paragraph>
</td>
<td align="center">
<paragraph>ethinyl<br/>estradiol:<br/>1.15<br/>(0.99, 1.32)<br/>norethindrone:<br/>1.67<br/>(1.42, 1.96)</paragraph>
</td>
<td align="center">
<paragraph>ethinyl<br/>estradiol:<br/>1.48<br/>(1.31, 1.68)<br/>norethindrone:<br/>2.10<br/>(1.68, 2.62)</paragraph>
</td>
<td align="center">
<paragraph>ethinyl<br/>estradiol:<br/>1.91<br/>(1.57, 2.33)<br/>norethindrone:<br/>3.62<br/>(2.57, 5.09)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>ethinyl estradiol  &amp; norgestimate<sup>e</sup>
</paragraph>
</td>
<td align="center">
<paragraph>Ortho Tri-Cyclen<sup>®</sup> QD, d 1–28 (n=18), then Ortho Tri-Cyclen<sup>®</sup> LO QD, d 29–42<sup>f</sup> (n=14)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD,  d 29–42  (n=14)</paragraph>
</td>
<td align="center">
<paragraph>ethinyl<br/>estradiol:<br/>0.84<br/>(0.74, 0.95)<br/>17-deacetyl<br/>norgestimate:<sup>g</sup>
<br/>1.68<br/> (1.51, 1.88)</paragraph>
</td>
<td align="center">
<paragraph>ethinyl<br/>estradiol:<br/> 0.81<br/> (0.75, 0.87)<br/> 17-deacetyl<br/>norgestimate:<sup>g</sup>
<br/> 1.85<br/> (1.67, 2.05)</paragraph>
</td>
<td align="center">
<paragraph>ethinyl<br/>estradiol:<br/> 0.63<br/> (0.55, 0.71)<br/> 17-deacetyl<br/>norgestimate:<sup>g</sup>
<br/> 2.02<br/> (1.77, 2.31)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>fluconazole</paragraph>
</td>
<td align="center">
<paragraph>200 mg QD, d 1−10 (n=11) and 200 mg QD, d 11−20 (n=29)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 11−20 (n=29)</paragraph>
</td>
<td align="center">
<paragraph>1.05<br/>(0.99, 1.10)</paragraph>
</td>
<td align="center">
<paragraph>1.08<br/>(1.02, 1.15)</paragraph>
</td>
<td align="center">
<paragraph>1.07<br/>(1.00, 1.15)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>methadone</paragraph>
</td>
<td align="center">
<paragraph>Stable maintenance dose, d 1−15 (n=16)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 2−15 (n=16)</paragraph>
</td>
<td align="center">
<paragraph>(R)-<br/>methadone<sup>h</sup>
<br/>0.91<br/>(0.84, 1.0)<br/>total: 0.85<br/>(0.78, 0.93)</paragraph>
</td>
<td align="center">
<paragraph>(R)-<br/>methadone<sup>h</sup>
<br/>1.03<br/>(0.95, 1.10)<br/>total: 0.94<br/>(0.87, 1.02)</paragraph>
</td>
<td align="center">
<paragraph>(R)-<br/>methadone<sup>h</sup>
<br/>1.11<br/>(1.02, 1.20)<br/>total: 1.02<br/>(0.93, 1.12)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>nevirapine<sup>i,j</sup>
</paragraph>
</td>
<td align="center">
<paragraph>200 mg BID, d 1–23 (n=23)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 4–13, then 400 mg QD/ritonavir 100 mg QD, d 14–23 (n=23)</paragraph>
</td>
<td align="center">
<paragraph>1.17<br/>(1.09, 1.25)<br/>1.21<br/>(1.11, 1.32)</paragraph>
</td>
<td align="center">
<paragraph>1.25<br/>(1.17, 1.34)<br/>1.26<br/>(1.17, 1.36)</paragraph>
</td>
<td align="center">
<paragraph>1.32<br/>(1.22, 1.43)<br/>1.35<br/>(1.25, 1.47)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>omeprazole<sup>k</sup>
</paragraph>
</td>
<td align="center">
<paragraph>40 mg single dose, d 7 and d 20 (n=16)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 1−12 (n=16)</paragraph>
</td>
<td align="center">
<paragraph>1.24<br/>(1.04, 1.47)</paragraph>
</td>
<td align="center">
<paragraph>1.45<br/>(1.20, 1.76)</paragraph>
</td>
<td align="center">
<paragraph>NA</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>rifabutin</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD, d 1−10 then 150 mg QD, d 11−20 (n=3)</paragraph>
</td>
<td align="center">
<paragraph>600 mg QD,<sup>l</sup> d 11−20 (n=3)</paragraph>
</td>
<td align="center">
<paragraph>1.18<br/>(0.94, 1.48)<br/>25-O-<br/>desacetyl-<br/>rifabutin: 8.20<br/>(5.90, 11.40)</paragraph>
</td>
<td align="center">
<paragraph>2.10<br/>(1.57, 2.79)<br/>25-O-<br/>desacetyl-<br/>rifabutin: 22.01<br/>(15.97, 30.34)</paragraph>
</td>
<td align="center">
<paragraph>3.43<br/>(1.98, 5.96)<br/>25-O-<br/>desacetyl-<br/>rifabutin: 75.6<br/>(30.1, 190.0)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph> </paragraph>
</td>
<td align="center">
<paragraph>150 mg twice weekly, d 1−15 (n=7)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 1−17 (n=7)</paragraph>
</td>
<td align="center">
<paragraph>2.49<sup>m</sup>
<br/>(2.03, 3.06)<br/>25-O-<br/>desacetyl-<br/>rifabutin: 7.77<br/>(6.13, 9.83)</paragraph>
</td>
<td align="center">
<paragraph>1.48<sup>m</sup>
<br/>(1.19, 1.84)<br/>25-O-<br/>desacetyl-<br/>rifabutin: 10.90<br/>(8.14, 14.61)</paragraph>
</td>
<td align="center">
<paragraph>1.40<sup>m</sup>
<br/>(1.05, 1.87)<br/>25-O-<br/>desacetyl-<br/>rifabutin: 11.45<br/>(8.15, 16.10)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>pitavastatin </paragraph>
</td>
<td align="center">
<paragraph>4 mg QD<br/>for 5 days</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD<br/>for 5 days</paragraph>
</td>
<td align="center">
<paragraph>1.60<br/>(1.39, 1.85)</paragraph>
</td>
<td align="center">
<paragraph>1.31<br/>(1.23, 1.39)</paragraph>
</td>
<td align="center">
<paragraph>NA</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>rosiglitazone<sup>n</sup>
</paragraph>
</td>
<td align="center">
<paragraph>4 mg single dose, d 1, 7, 17 (n=14)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 2–7, then 300 mg QD/ritonavir 100 mg QD, d 8–17 (n=14)</paragraph>
</td>
<td align="center">
<paragraph>1.08<br/>(1.03, 1.13)<br/>0.97<br/>(0.91, 1.04)</paragraph>
</td>
<td align="center">
<paragraph>1.35<br/>(1.26, 1.44)<br/>0.83<br/>(0.77, 0.89)</paragraph>
</td>
<td align="center">
<paragraph>NA<br/>
<br/>NA</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>rosuvastatin</paragraph>
</td>
<td align="center">
<paragraph>10 mg<br/>single dose</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/<br/>ritonavir 100 mg<br/>QD for 7 days</paragraph>
</td>
<td align="center">
<paragraph>↑ 7-fold<sup>o</sup>
</paragraph>
</td>
<td align="center">
<paragraph>↑ 3-fold<sup>o</sup>
</paragraph>
</td>
<td align="center">
<paragraph>NA</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>saquinavir<sup>p</sup> (soft gelatin capsules)</paragraph>
</td>
<td align="center">
<paragraph>1200 mg QD, d 1−13 (n=7)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 7−13 (n=7)</paragraph>
</td>
<td align="center">
<paragraph>4.39<br/>(3.24, 5.95)</paragraph>
</td>
<td align="center">
<paragraph>5.49<br/>(4.04, 7.47)</paragraph>
</td>
<td align="center">
<paragraph>6.86<br/>(5.29, 8.91)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>telaprevir</paragraph>
</td>
<td align="center">
<paragraph>750 mg q8h<br/>for 10 days<br/>(n=14)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/<br/>ritonavir 100 mg<br/>QD for 20 days<br/>(n=14)</paragraph>
</td>
<td align="center">
<paragraph>0.79<br/>(0.74, 0.84)</paragraph>
</td>
<td align="center">
<paragraph>0.80<br/>(0.76, 0.85)</paragraph>
</td>
<td align="center">
<paragraph>0.85<br/>(0.75, 0.98)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>tenofovir<sup>q</sup>
</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD, d 9−16 (n=33) and d 24−30 (n=33)</paragraph>
</td>
<td align="center">
<paragraph>400 mg QD, d 2−16 (n=33)</paragraph>
</td>
<td align="center">
<paragraph>1.14<br/>(1.08, 1.20)</paragraph>
</td>
<td align="center">
<paragraph>1.24<br/>(1.21, 1.28)</paragraph>
</td>
<td align="center">
<paragraph>1.22<br/>(1.15, 1.30)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph> </paragraph>
</td>
<td align="center">
<paragraph>300 mg QD, d 1−7 (pm) (n=14) d 25−34 (pm) (n=12)</paragraph>
</td>
<td align="center">
<paragraph>300 mg QD/ritonavir 100 mg QD, d 25−34 (am) (n=12)<sup>r</sup>
</paragraph>
</td>
<td align="center">
<paragraph>1.34<br/>(1.20, 1.51)</paragraph>
</td>
<td align="center">
<paragraph>1.37<br/>(1.30, 1.45)</paragraph>
</td>
<td align="center">
<paragraph>1.29<br/>(1.21, 1.36)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>voriconazole<br/>(Subjects with at least one functional CYP2C19 allele)</paragraph>
</td>
<td align="center">
<paragraph>200 mg BID, d 2−3, 22−30; <br/> 400 mg BID, d 1, 21 (n=20)</paragraph>
</td>
<td align="center">
<paragraph>300 mg/ritonavir 100 mg QD, d 11−30 (n=20)</paragraph>
</td>
<td align="center">
<paragraph>0.90<br/>(0.78, 1.04)</paragraph>
</td>
<td align="center">
<paragraph>0.67<br/>(0.58, 0.78) </paragraph>
</td>
<td align="center">
<paragraph>0.61<br/>(0.51, 0.72)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>voriconazole<br/>(Subjects without a functional CYP2C19 allele)</paragraph>
</td>
<td align="center">
<paragraph>50 mg BID, d 2−3, 22−30; <br/> 100 mg BID, d 1, 21 (n=8)</paragraph>
</td>
<td align="center">
<paragraph>300 mg/ritonavir 100 mg QD, d 11−30 (n=8)</paragraph>
</td>
<td align="center">
<paragraph>4.38<br/>(3.55, 5.39)</paragraph>
</td>
<td align="center">
<paragraph>5.61<br/>(4.51, 6.99) </paragraph>
</td>
<td align="center">
<paragraph>7.65<br/>(5.71, 10.2)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule ">
<paragraph>lamivudine + zidovudine</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>150 mg lamivudine + 300 mg zidovudine BID, d 1−12 (n=19)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>400 mg QD, d 7−12 (n=19)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>lamivudine: 1.04<br/>(0.92, 1.16)<br/>zidovudine: 1.05<br/>(0.88, 1.24)<br/>zidovudine<br/>glucuronide: 0.95<br/>(0.88, 1.02)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>lamivudine: 1.03<br/>(0.98, 1.08)<br/>zidovudine: 1.05<br/>(0.96, 1.14)<br/>zidovudine<br/>glucuronide: 1.00<br/>(0.97, 1.03)</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>lamivudine: 1.12<br/>(1.04, 1.21)<br/>zidovudine: 0.69<br/>(0.57, 0.84)<br/>zidovudine<br/>glucuronide: 0.82<br/>(0.62, 1.08)</paragraph>
</td>
</tr>
</tbody>
</table>